DOI: https://doi.org/10.30841/2307-5112.2.2018.145510

Синдром гипергемолиза: теория и практика

С. В. Видиборець, С. М. Гайдукова, О. В. Кучер, Г. І. Мороз

Аннотация


Представлена подробная информация об этиологии, патогенезе, клинических проявлениях, профилактике и лечении тяжелого осложнения трансфузионной терапии эритроцитной массой – гипергемолизе. Синдром гипергемолиза – грозное осложнение трансфузионной терапии эритроцитной массой у пациентов различного возраста, которое чаще встречается при серповидно-клеточной болезни и бета-таласемии, но может быть и при лимфомах, анемии хронического заболевания. Патогенез развития этого синдрома до конца не изучен и нет однозначных рекомендаций по его лечению. В настоящем обзоре представлен анализ имеющейся на данную тему литературы, отражающей терминологию, возможные механизмы развития, клинические проявления и лечение.


Ключевые слова


синдром гипергемолиза; отсроченные посттрансфузионные осложнения; гемолитическая трансфузионная реакция; серповидно-клеточная болезнь; анемия хронического заболевания

Полный текст:

PDF (Українська)

Литература


Aygun B., Padmanabhan S., Paley C., Chandrasekaran V. Clinical significance of RBC alloantibodies and autoantibodies in sickle cell patients who received transfusions. Transfusion. 2002, vol. 42, no.1, pp. 37–43. https://doi.org/10.1046/j.1537-2995.2002.00007.x

Babb A., Diamantos N., Sekhar M. Hyperhemolysis syndrome treated with corticosteroids and darbopoietin in patients with malte cell lymphoma. Transfus. Med., 2012, vol. 22, no.2, pp. 142–144. https://doi.org/10.1111/j.1365-3148.2011.01095.x

Bachmeyer C., Maury J., Parrot A. et al. Rituximab as an effective treatment of hyperhemolysis syndrome in sickle cell anemia. Am. J. Hematol., 2010, vol. 85, no.1, pp. 91–92. https://doi.org/10.1002/ajh.21578

Ballas S.K., Marclina M.J. Hyperhemolysis during the evolution of uncomplicated acute painful episodes in patients with sickle cell anemia. Transfusion, 2006. – vol. 46, no.1, pp. 105–110. https://doi.org/10.1111/j.1537-2995.2006.00679.x

Benson K., Agosti S.J., Latoni-Benedetti G.E. Acute and delayed hemolytic transfusion reactions secondary to HLA alloimmunization. Transfusion. – 2003, vol. 43, no.6, pp. 753–757. https://doi.org/10.1046/j.1537-2995.2003.00381.x

Chadebech P., Habibi A., Nzouakou R. et al. Delayed hemolytic transfusion reaction in sickle cell disease patients: avidence of an emerging syndrome with suicidal red blood cell death. Transfusion, 2009, vol.49, no.9, p. 1785–1792. https://doi.org/10.1111/j.1537-2995.2009.02199.x

Darabi K., Dzik S. Hyperhaemolysis syndrome in anemia of chronic disease. Transfusion, 2005, vol.45, no. 12, pp. 1930–1933. https://doi.org/10.1111/j.1537-2995.2005.00608.x

Delmonte L., Cantini M., Olivieri O., De Franceschi L. Immunoglobulin resistant delayed hemolytic transfusion reaction treated with rituximab in an adult sickle cell patient. Transfusion, 2013, vol. 53, no.3, pp. 688–689. https://doi.org/10.1111/trf.12090

De Montalembert M., Dumont M.D., Heilbronner C. et al. Delayed hemolytic transfusion reaction in children with sickle disease. Hematologica, 2011, vol.96, no.6, pp. 801–807. https://doi.org/10.3324/haematol.2010.038307

El-Husseini A., Sabry A. Fatal hyperhemolytic delayed transfusion reaction in sickle cell disease: a case report and literature review. Am. J. Emerg. Med., 2010, vol. 28, no.9, pp. e5-8. https://doi.org/10.1016/j.ajem.2010.01.032

Garratty G. The James Blundell Award Lecture: do we really understand immune red cell destruction? Transfus. Med. 2008, vol. 18, no.6, pp. 321-334. https://doi.org/10.1111/j.1365-3148.2008.00891.x

Garratty G. What do we mean by «hyperhemolysis» and what is the cause? Trandfus.Med. – 2012. – vol.22, no.2, pp. 77–79. https://doi.org/10.1111/j.1365-3148.2012.01151.x

Grainger J.D., Makar Y., McManus A., Wynn R. Refractory hyperhaemolysis in a patient with beta-thalassaemia major. Transfus. Med. – 2001. – vol.11, no.1, pp. 55–57. https://doi.org/10.1046/j.1365-3148.2001.00278.x

Hannema S.E., Brand A., van Meurs A., Smiers F.G. Delayed hemolytic transfusion reaction with hyperhemolysis after first red cell transfusion in child with beta-thalassemia: challender in treatment. Transfusion, 2010, vol.50, no.2, pp. 429–432. https://doi.org/10.1111/j.1537-2995.2009.02399.x

Islam M.S., Chia L. Hyperhemolysis syndrome in a patient with sickle cell disease with erythrophagocytosis in peripheral blood. Eur. J. Haematol., 2010, vol.84, no.2, p. 188. https://doi.org/10.1111/j.1600-0609.2009.01351.x

McGlennan A.P., Grundy E.M. Delayed hemolytic transfusion reaction and hyperhemolysis complicating peri-operative blood transfusion in sickle cell disease. Anaesthesia, 2005, vol.60, no.6, pp. 609-612. https://doi.org/10.1111/j.1365-2044.2005.04188.x

McCullough J. (ed.) Transfusion medicine. – 4th ed., Wiley Blackwell, 2017. – 603 p.

Muro M., Palacios S., Moya-Quiles R. et al. Acute hemolytic transfusion reactions secondary to human leukocyte antigen alloimmunization. Int. J. Lab. Hematol., 2008, vol.30, no.1, pp. 84–86. https://doi.org/10.1111/j.1751-553X.2006.00889.x

Noizat-Pirenne F., Bachir D., Chadebech P. et al. Rituximab for prevention of delayed hemolytic transfusion reaction in sickle cell disease. Haematologica. 2007, vol. 92, no.12, pp. e132–135. https://doi.org/10.3324/haematol.12074

Peltz L.D. Bystander immune cytolysis. Transfus. Med. Rev. 2006. – vol. 20, no.21, pp. 110–140. https://doi.org/10.1016/j.tmrv.2005.11.002

Ragimov A.A. (ed.) Transfusiologija: nazional’noe rukovodstvo. Moskva: GEOTAR-Media, 2012, 1184 p.

Rukavitsyn O.A. (ed.) Gematologija: nazional’noe rukovodstvo [Hematology: textbook]. Moskva: GEOTAR-Media, 2015, 776 p.

Scheunemann L.P., Ataga K.I. Delayed hemolytic transfusion reaction in sickle cell disease. Am. J. Med. Sci., 2010, vol.339, no.3, pp. 266–269. https://doi.org/10.1097/MAJ.0b013e3181c70e14

Shamov I.A., Bajgishieva N.Ch. Serpovidnokletochnaja bolezn’ [Sickle cell diseases]. – Mahachkala: izdatel’sko poligraficheskij zentr DGMA, 2006. – 160 p.

Sheiman B.S., Voloshina N.A., Safronova I.A., Urin A.A. Ostraja gemoliticheskaja anemija i ostroe povrezhdenije pochek (profilaktika i lechenije). Bil’, zneboluvannja і intensivnaja terapija, 2013, no.4, pp. 33–39.

Takeuchi C., Ohto H., Miura S. et al. Delayed and acute hemolytic transfusion reactions resulting from red cell antibodies and red cell-reactive HLA antibodies. Transfusion, 2005, vol. 45, no.12, pp. 1925–1929. https://doi.org/10.1111/j.1537-2995.2005.00607.x

Talano J.A., Hillery C.A., Guttshall J.L., Scott J.P. Delayed hemolytic transfusion reaction / hyperhemolysis syndrome in children with sickle disease. Pediatrics, 2003, vol.111, no.6, pt.1, e661–665.

Taylor J.G., Nolan V.G., Mendelsohn L., Kato G.J., Gladwin M.T., Steinberg M.H. Chronic hyperhemolysis in sickle cell anemia: association of vascular complications and mortality with less frequent vasoocclusive pain. PloS One. – 2008. – no. 2(5), e2095. https://dx.doi.org/10.1371%2Fjournal.pone.0002095

Volkova M. A. (2007) Сlinical oncohematology. A manual for the physician. Ed. by M.A. Volkova. 2nd edition, updated. Moskow: Meditsina Publichers. – 1120 p.

Win N. Hyperhemolysis syndrome in sickle cell disease. Expert Rev. Hematol. – 2009. – vol. 2, no. 2, pp. 111–115. https://doi.org/10.1586/ehm.09.2

Win N., Lee E., Needs M. et al. Measurement of macrophage marker in hyperhemolytic transfusion reaction: a case report. Transfus. Med. 2012, vol.22, no.2, pp. 137–141. https://doi.org/10.1111/j.1365-3148.2011.01131.x

Win N., New H., Lee E., de la Fuente J. Hyperhemolysis syndrome in sickle cell disease: case report (recurrent episode) and literature review. Transfusion, 2008, vol. 48, no.6, pp. 1231–1238. https://doi.org/10.1111/j.1537-2995.2008.01693.x

Win N., Sincha S., Lee E., Mills W. Treatment with intravenous immunoglobulin and steroids may correct severe anemia in hyperhemolytic transfusion reactions: case report and literature review. Transfus. Med. Rev. 2010. – vol. 24, no.1, pp. 64–67. https://doi.org/10.1016/j.tmrv.2009.09.006

Wintrobe’s clinical hematology / [ed. by J.P. Greer, D.A. Arber, B. Glader et al.], 13th ed., Philadelphia: Lippincott Williams & Wilkins, 2014. – 2278 p.

Yazdanbakhsh K., Ware R.E., Noizat-Pirenne F. Red blood cell alloimmunization in sickle cell disease: pathophysiology, risk factors, and transfusion management. Blood. 2012, vol.120, no.3, pp. 528–537. https://doi.org/10.1182/blood-2011-11-327361

Zimring J.C., Spitalnik S.L. To RBC or not to RBC: the role of suicidal death in hemolytic transfusion reactions. Transfusion, 2009, vol.49, no.9, pp. 1776–1778. https://doi.org/10.1111/j.1537-2995.2009.02339.x




Copyright (c) 2018 Семейная медицина

Creative Commons License
Эта работа лицензирована Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

ISSN 2412-8708 (Online), ISSN 2307-5112 (Print)

Flag Counter